Endocrinology, Diabetes & Metabolism Doctors in Fayetteville, GA Accepting Medicare

3 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 3

Dr. Annie Quinn Morrissey, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1265 Highway 54 W Ste 302, Fayetteville, GA 30214 Phone: 770-506-1590

Dr. Anuradha Guthikonda, M.D Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1265 Highway 24 West, Suite 302, Fayetteville, GA 30214 Phone: 770-506-1590

Kelly Natasha Wood, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1265 Highway 54 W Ste 302, Fayetteville, GA 30214 Phone: 770-506-1590

News Archive

Water-limited landscapes can facilitate disease transmission

In water-limited landscapes sick animals can have increased contact with healthy individuals, which can facilitate disease transmission. Scientists from the German Leibniz Institute for Zoo and Wildlife Research present these findings in the British Ecological Society journal Functional Ecology.

Cellular recycling process may prevent cancer initiation, finds study

Just as plastic tips protect the ends of shoelaces and keep them from fraying when we tie them, molecular tips called telomeres protect the ends of chromosomes and keep them from fusing when cells continually divide and duplicate their DNA.

PHARMABIZ.com examines India's push for clearer definition of counterfeit, substandard medicines

India has taken the lead to get together a number of generic drug-producing nations to call for better definitions to ensure quality, strengthening of regulatory authorities in the respective countries, and bringing focus of the world to public health instead of intellectual property, PHARMABIZ.com writes in an article that examines the recent meeting of leaders from Brazil, India and South Africa on issues regarding counterfeit medicines.

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

Read more Medical News

› Verified 7 days ago